The University of Chicago Header Logo

Connection

Tao Xie to Supranuclear Palsy, Progressive

Back to Details
This is a "connection" page, showing publications Tao Xie has written about Supranuclear Palsy, Progressive.
Tao Xie
Connection Strength
5.236
Supranuclear Palsy, Progressive
  1. Bedside Assessment of Downgaze Limit by Amplitude. Mov Disord Clin Pract. 2025 Dec; 12(12):2224-2231.
    View in: PubMed
    Score: 0.891
  2. Using Downgaze Palsy Progression Rate to Model Survival in Progressive Supranuclear Palsy-Richardson Syndrome. Mov Disord. 2023 02; 38(2):304-312.
    View in: PubMed
    Score: 0.747
  3. Disease course and treatment patterns in progressive supranuclear palsy: A real-world study. J Neurol Sci. 2021 Feb 15; 421:117293.
    View in: PubMed
    Score: 0.650
  4. Brain Atrophy Does Not Predict Clinical Progression in Progressive Supranuclear Palsy. Mov Disord. 2025 Nov; 40(11):2517-2530.
    View in: PubMed
    Score: 0.450
  5. Magnetic Resonance Imaging Measures to Track Atrophy Progression in Progressive Supranuclear Palsy in Clinical Trials. Mov Disord. 2024 Aug; 39(8):1329-1342.
    View in: PubMed
    Score: 0.413
  6. Severity dependent distribution of impairments in PSP and CBS: Interactive visualizations. Parkinsonism Relat Disord. 2019 03; 60:138-145.
    View in: PubMed
    Score: 0.277
  7. CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP. Neurology. 2018 01 23; 90(4):e273-e281.
    View in: PubMed
    Score: 0.264
  8. Progression of brain atrophy in PSP and CBS over 6 months and 1 year. Neurology. 2016 Nov 08; 87(19):2016-2025.
    View in: PubMed
    Score: 0.243
  9. Language impairment is associated with faster progression in progressive supranuclear palsy-Richardson syndrome. Alzheimers Dement. 2025 Jul; 21(7):e70485.
    View in: PubMed
    Score: 0.222
  10. Automated Imaging Differentiation for Parkinsonism. JAMA Neurol. 2025 May 01; 82(5):495-505.
    View in: PubMed
    Score: 0.220
  11. Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol. 2014 Jul; 13(7):676-85.
    View in: PubMed
    Score: 0.206
  12. Recommendations for Virtual Administration of the PSP Rating Scale. Mov Disord. 2022 09; 37(9):1960-1961.
    View in: PubMed
    Score: 0.181
  13. A Modified Progressive Supranuclear Palsy Rating Scale for Virtual Assessments. Mov Disord. 2022 06; 37(6):1265-1271.
    View in: PubMed
    Score: 0.177
  14. Development and validation of the automated imaging differentiation in parkinsonism (AID-P): a multicentre machine learning study. Lancet Digit Health. 2019 09; 1(5):e222-e231.
    View in: PubMed
    Score: 0.148
  15. Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial. Lancet Neurol. 2019 06; 18(6):549-558.
    View in: PubMed
    Score: 0.146
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.